Effects of a new calcium antagonist, mibefradil (Ro 40-5967), on silent ischemia in patients with stable chronic angina pectoris: A multicenter placebo-controlled study

Journal of the American College of Cardiology

Volumn 27, Issue 2, 1996, Pages 317-322

  Braun, Shimon ^a   Van Der Wall, Ernst E ^a,b   Emanuelsson, Hakan ^a,c   Kobrin, Isaak ^a,d  

^a TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^c SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^d F HOFFMANN LA ROCHE LTD   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM ANTAGONIST; MIBEFRADIL; PLACEBO;

ADULT; AGED; ANGINA PECTORIS; ARTICLE; ATRIOVENTRICULAR BLOCK; BRADYCARDIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DOUBLE BLIND PROCEDURE; ELECTROCARDIOGRAM; FEMALE; FIRST DEGREE HEART BLOCK; HOLTER MONITORING; HUMAN; INOTROPISM; ISCHEMIA; LEG ISCHEMIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; ST SEGMENT DEPRESSION;

EID: 0030067254     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/0735-1097(95)00472-6     Document Type: Article

References (34)

1. Deanfield JE, Maseri A, Selwyn AP, et al. Myocardial ischemia during daily life in patients with stable angina: its relation to symptoms and heart rate changes. Lancet 1983;2:753-8.
2. Quyyumi AA, Mockus L, Wright C, et al. Morphology of ambulatory ST segment changes in patients with varying severity of coronary artery disease. Investigation of the frequency of nocturnal ischaemia and coronary spasm. Br Heart J 1985;53:186-93.
3. Newman GF, Rerych SK, Upton MT, et al. Comparison of electrocardiographic and left ventricular functional changes during exercise. Circulation 1980;62:1204-11.
4. Stern S, Tzivoni D. Early detection of silent ischemic heart disease by 24-hour electrocardiographic monitoring of active subject. Br Heart J 1974;36:481-6.
5. Campbell S, Barry J, Rocco M, et al. Features of the exercise test that reflect the activity of ischemic heart disease out of hospital. Circulation 1986;74: 72-80.
6. Deedwania PC, Carbajal EV. Exercise test predictors of ambulatory silent ischemia during daily life in stable angina pectoris. Am J Cardiol 1990;66: 1151-6.
7. Hinderliter A, Miller P, Bragdon E, et al. Myocardial ischemia during daily activities: the importance of increased myocardial oxygen demand. J Am Coll Cardiol 1991;18:405-12.
8. Mulcahy D, Keegan J, Sparrow J, et al. Ischemia in the ambulatory setting - the total ischemic burden: relation to exercise testing and investigative and therapeutic implications. J Am Coll Cardiol 1989;14:1166-72.
9. Panza J, Quyyumi A, Diodati J, et al. Prediction of the frequency and duration of ambulatory myocardial ischemia in patients with stable coronary artery disease by determination of the ischemic threshold from exercise testing: importance of the exercise protocol. J Am Coll Cardiol 1991;17:657-63.
10. Strauss WE, Parisi AF. Combined use of calcium-channel and beta-adrenergic blockers for the treatment of chronic stable angina. Ann Intern Med 1988;109:570-81.
11. Clozel JP, Banken L, Osterrieder W. Effects of Ro 40-5967, a novel calcium antagonist, on myocardial function during ischemia induced by lowering coronary perfusion pressure in dogs: comparison with verapamil. J Cardiovasc Pharmacol 1989;14:713-21.
12. Guth BD. Reduction of exercise-induced regional contractile dysfunction in dogs using a novel calcium channel blocker (Ro 40-5967). Cardiovasc Drugs Ther 1992;6:167-71.
13. 2+ channel blocker with potent vasodilator but weak inotropic action. J Cardiovasc Pharmacol 1989;13:754-9.
14. Clozel JP, Osterrieder W, Kleinbloesem CH, et al. Ro 40-5967: a new nondihydropyridine calcium antagonist. Cardiovasc Drug Rev 1991;9:4-17.
15. 3H] desmethoxyverapamil receptor, is devoid of the negative inotropic effects of verapamil in normal and failing rat hearts. Cardiovasc Drugs Ther 1990;4:731-6.
16. Portegies MCM, Schmitt R, Kraaij CJ, et al. Lack of negative inotropic effects of the new calcium antagonist Ro 40-5967 in patients with stable angina pectoris. J Cardiovasc Pharmacol 1991;18:746-51.
17. 2+ channel antagonist Ro 40-5967 in vascular smooth muscle cells cultured from dog coronary and saphenous arteries. Arch Pharmacol 1993;348:191-6.
18. Ezzaher A, Bouanani NEH, Su JB, Hittinger L, Crozatier B. Increased negative inotropic effect of calcium-channel blockers in hypertrophied and failing rabbit heart. J Pharmacol Exp Ther 1991;257:466-71.
19. Schmitt R, Kleinboloesem CH, Belz GG, et al. Hemodynamic and humoral effects of the novel calcium antagonist Ro 40-5967 in patients with hypertension. Clin Pharmacol Ther 1992;52:314-23.
20. Orito K, Sateh K, Nurio T. Cardiovascular profile of Ro 40-5967, a new non-dihydropyridine calcium antagonist, delineated in isolated blood perfused dog hearts. J Cardiovasc Pharmacol 1993;22:293-9.
21. Bakx LM, Van der Wall EE, Braun S, Emanuelson H, Bruschke AVG, Kobrin I. The effects of the new calcium antagonist Mibefradil (Ro 40-5967) on exercise duration in patients with chronic stable angina pectoris: a multicenter placebo-controlled study. Am Heart J 1995;130:748-57.
22. Hollander M, Wolfe DA. Nonparametric Statistical Methods. New York: Wiley 1973:194-8.
23. Budd M, Bauer P. Multiple test procedure in clinical dose finding trails. J Am Stat Assoc 1989;84:792-6.
24. Bala Subramanian V, Bowles MJ, Khurmi NS, et al. Rationale for the choice of calcium antagonists in chronic stable angina: an objective double-blind, placebo-controlled comparison of nifedipine and verapamil. Am J Cardiol 1982;50:1173-9.
25. Frishman W, Charlap S, Kimmel B, et al. Diltiazem, nifedipine, and their combination in patients with stable angina pectoris: effects on angina, exercise tolerance, and the ambulatory electrocardiographic ST-segment. Circulation 1988;77:774-86.
26. Deedwania PC, Carbajal EV, Nelson JR, et al. Anti-ischemic effects of atenolol versus nifedipine in patients with coronary artery disease and ambulatory silent ischemia. J Am Coll Cardiol 1991;17:963-9.
27. Theroux P, Baird M, Juneau M, et al. Effect of diltiazem on symptomatic and asymptomatic episodes of ST segment depression occurring during daily life and during exercise. Circulation 1991;84:15-22.
28. Stone PH, Gibson RS, Glasser SP, et al. Comparison of propranolol, diltiazem, and nifedipine in the treatment of ambulatory ischemia in patients with stable angina: differential effects on ambulatory ischemia, exercise performance, and anginal symptoms. Circulation 1990;82:1962-72.
29. 2+ channels by Ro 40-5967. Circ Res 1995;75:144-7.
30. Parmley WW, Nesto RW, Singh BN, et al. Attenuation of the circadian patterns of myocardial ischemia with nifedipine GITS in patients with chronic stable angina. J Am Coll Cardiol 1992;19:1380-9.
31. Brown BG, Lee AB, Bolson EL, et al. Reflex constriction of significant coronary stenosis as a mechanism contributing to ischemic left ventricular dysfunction during isometric exercise. Circulation 1984;70:18-24.
32. Brown BG, Bolson EL, Dodge HT. Dynamic mechanisms in human coronary stenosis. Circulation 1984;70:917-22.
33. Brown GB. Coronary vasospasm. Observations linking the clinical spectrum of ischemic heart disease to the dynamic pathology of coronary atherosclerosis. Arch Intern Med 1981;141:716-22.
34. Gage JE, Hess OM, Murakami T, et al. Vasoconstriction of stenotic coronary arteries during dynamic exercise in patients with classic angina pectoris: reversibility by nitroglycerin. Circulation 1986;73:865-76.